⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory medulloblastoma

Every month we try and update this database with for refractory medulloblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250
Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 YearsNational Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994
Advanced Malign...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Wilms Tumor
Pharmacokinetic...
Ulixertinib
12 Months - 21 YearsNational Cancer Institute (NCI)
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsNCT03598244
Recurrent Diffu...
Recurrent Malig...
Recurrent Medul...
Recurrent Prima...
Refractory Diff...
Refractory Mali...
Refractory Medu...
Refractory Prim...
Biospecimen Col...
Magnetic Resona...
Savolitinib
X-Ray Imaging
6 Years - 21 YearsNational Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774
Malignant Solid...
Recurrent Adren...
Recurrent Ectom...
Recurrent Epend...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Melan...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent Thyro...
Recurrent WHO G...
Refractory Adre...
Refractory Epen...
Refractory Ewin...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Mela...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Refractory Thyr...
Refractory WHO ...
Biospecimen Col...
Bone Marrow Asp...
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Radionuclide Im...
Tipifarnib
12 Months - 21 YearsNational Cancer Institute (NCI)
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNCT04320888
Hematopoietic a...
Recurrent Epend...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Lymph...
Recurrent Malig...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent WHO G...
Refractory Epen...
Refractory Ewin...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Lymp...
Refractory Mali...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Refractory WHO ...
Wilms Tumor
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Radionuclide Im...
Selpercatinib
X-Ray Imaging
12 Months - 21 YearsNational Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994
Advanced Malign...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Wilms Tumor
Pharmacokinetic...
Ulixertinib
12 Months - 21 YearsNational Cancer Institute (NCI)
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal TumorsNCT01217437
Central Nervous...
Pineoblastoma
Recurrent Medul...
Recurrent Primi...
Refractory Medu...
Refractory Peri...
Bevacizumab
Irinotecan Hydr...
Temozolomide
- 21 YearsNational Cancer Institute (NCI)
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsNCT02095132
Central Nervous...
Central Nervous...
Central Nervous...
Embryonal Tumor...
Pineoblastoma
Primary Central...
Recurrent Child...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Rhabd...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Rhab...
Adavosertib
Irinotecan Hydr...
1 Year - 21 YearsNational Cancer Institute (NCI)
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or MedulloblastomaNCT00867568
Neuroblastoma
Medulloblastoma
Relapse
TPI 287
12 Months - 21 YearsMilton S. Hershey Medical Center
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsNCT03598244
Recurrent Diffu...
Recurrent Malig...
Recurrent Medul...
Recurrent Prima...
Refractory Diff...
Refractory Mali...
Refractory Medu...
Refractory Prim...
Biospecimen Col...
Magnetic Resona...
Savolitinib
X-Ray Imaging
6 Years - 21 YearsNational Cancer Institute (NCI)
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaNCT02359565
Constitutional ...
Lynch Syndrome
Malignant Gliom...
Recurrent Brain...
Recurrent Child...
Recurrent Diffu...
Recurrent Medul...
Refractory Brai...
Refractory Diff...
Refractory Epen...
Refractory Medu...
Biospecimen Col...
Conventional Ma...
Diffusion Tenso...
Diffusion Weigh...
Dynamic Contras...
Dynamic Suscept...
Magnetic Resona...
Pembrolizumab
1 Year - 30 YearsNational Cancer Institute (NCI)
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsNCT05278208
High Grade Glio...
Meningioma
Embryonal Tumor
Medulloblastoma
Anaplastic Epen...
Recurrent Diffu...
Recurrent Malig...
Recurrent Medul...
Recurrent Prima...
Refractory Diff...
Refractory Mali...
Refractory Medu...
Refractory Prim...
LUTATHERA® (Lut...
4 Years - Nationwide Children's Hospital
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620
Advanced Malign...
Ann Arbor Stage...
Ann Arbor Stage...
Histiocytic Sar...
Juvenile Xantho...
Langerhans Cell...
Malignant Gliom...
Recurrent Child...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Rhabdoid Tumor
Stage III Osteo...
Stage III Soft ...
Stage IV Osteos...
Stage IV Soft T...
Stage IVA Osteo...
Stage IVB Osteo...
Wilms Tumor
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Bone Scan
Computed Tomogr...
Ensartinib
Erdafitinib
Laboratory Biom...
Larotrectinib S...
Magnetic Resona...
Mutation Carrie...
Olaparib
Palbociclib
Pharmacological...
Positron Emissi...
Radionuclide Im...
Samotolisib
Selpercatinib
Selumetinib Sul...
Tazemetostat
Tipifarnib
Ulixertinib
Vemurafenib
X-Ray Imaging
12 Months - 21 YearsNational Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250
Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 YearsNational Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: